Using a Composite Summary of Daily Sex Hormones to Gauge Time Until Menopause: A Focus on Pregnanediol Glucuronide (PDG) - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessing Time to Menopause Through a Composite Analysis of Daily Sex Hormones: Emphasis on Pregnanediol Glucuronide (PDG)

  • By

  • J F Winkles

  • Alicia Colvin

  • Samar R El Khoudary

  • Nanette Santoro

  • Mary Sammel

  • Sybil Crawford

  • January 23, 2025

Share

  • 1

    The timing of a woman's final menstrual period (FMP) is linked to various health outcomes, including cardiovascular and bone health.

  • 2

    Pregnanediol glucuronide (PDG) is identified as a significant predictor of time to FMP, challenging previous assumptions about hormone relevance.

  • 3

    The study utilized daily hormone measurements to analyze hormone trajectories using Fuzzy entropy and dynamic time warping methods.

  • 4

    Cluster analyses revealed distinct survival curves based on PDG levels, indicating varying risk profiles for experiencing FMP.

  • 5

    This research introduces a new analytical framework for assessing ovarian aging and highlights PDG's role in preventive care related to menopause.

Original Source(s)

Using a Composite Summary of Daily Sex Hormones to Gauge Time Until Menopause: A Focus on Pregnanediol Glucuronide (PDG)

  • by J F Winkles, Alicia Colvin, Samar R El Khoudary, Nanette Santoro, Mary Sammel, Sybil Crawford

  • January 23, 2025

Related Content

Menopause may be underdocumented in EHRs

Surveys captured nearly 7 times as many menopause observations as structured clinical records, with high agreement when both sources identified menopause.

Greater amounts of visceral adipose and lean body mass increase heart failure risk in older women

Medical Oddities: Could GLP-1s Curb Violence?

Five studies, one question: are we overlooking hidden drivers of health?